However, the expectation among many experts is that they may be effective in certain subsets of Sjogrens patients, and offer incremental therapeutic benefit, rather than a panacea
In this context, the seminal SYNERGY-NASH trial has shown that, by week 52, tirzepatide administration was more effective than placebo in achieving histologic MASH improvement without exacerbating fibrosis, an endpoint supported by the Food and Drug Administration [10]
PCOS is associated with specific gene mutations, and most gene variants identified in genome-wide association studies are involved in regulating sheath steroid production, follicular maturation, or insulin signalling through the modified proteins they encode, such as insulin receptors, LH/HCG receptor activators, cell traffic proteins, and transcription factors [31, 32]
The second is an observational study in JMIR mHealth
Starting with the question of whether semaglutide has the potential to enhance sport performance, as of early 2026, theres no published, peer-reviewed clinical trials directly measuring whether GLP-1 agonists improve athletic performance in trained, healthy athletes
Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes: a randomized controlled trial